IN THE SPOTLIGHT

473  Tales of Antigen Evasion from CAR Therapy
     Michel Sadelain
     See related articles, pp. 498 and 509.

CANCER IMMUNOLOGY MINIATURES

474  Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy
     Allison R. Greenplate, Douglas B. Johnson, Mikael Roussel, Michael R. Savona, Jeffrey A. Sosman, Igor Puzanov, P. Brent Ferrell Jr, and Jonathan M. Irish
     It has become crucial to understand immunotherapy-induced changes to the immune system. Mass cytometry allowed the in-depth monitoring of multiple immune subsets during a patient’s therapy, detecting an emerging myelodysplasia and providing insights into the therapeutic response.

481  Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases
     Patients undergoing stereotactic radiosurgery for brain metastases may show unexpected effects in the lesions after treatment with antibodies to PD-1. Assessments of clinical and radiologic changes need accurate interpretation in this growing patient population.

RESEARCH ARTICLES

488  Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype
     Run Xiao, Stephen M. Bergin, Wei Huang, Andrew M. Slater, Xianglan Liu, Ryan T. Judd, En-Ju D. Lin, Kyle J. Widstrom, Steven D. Scoville, Jianhua Yu, Michael A. Caligiuri, and Lei Cao
     Housing mice in enriched environments with multiple stimuli modulated T-cell immunity and inhibited cancer progression. Enhanced immunity was mediated by hypothalamic BDNF, supporting the concept that manipulating a single gene in the brain can improve cancer immunotherapy.

498  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
     Eugenia Zhai, Meng-Yin Lin, Anne Silva-Benedict, Michael C. Jensen, and Yvonne Y. Chen
     Bispecific chimeric antigen receptors (CARs) have been systematically optimized to simultaneously target two clinically relevant antigens, CD19 and CD20, presenting a clinically applicable solution to antigen escape and facilitating the rational design of receptors with higher-level complexities.

509  Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
     Gregory A. Ruffner, Oliver W. Press, Philip Olsen, Sang Yun Lee, Michael C. Jensen, Ajay K. Gopal, Barbara Pender, Liliana E. Budde, Jeffrey K. Rossow, Damian J. Green, David G. Maloney, Stanley R. Riddell, and Brian G. Till
     Most patients with B-cell lymphoma are treated with mAbs to CD20, which might interfere with subsequent chimeric antigen receptor (CAR) T cells against CD20. However, function was preserved in vivo in the presence of clinically relevant rituximab concentrations and only modestly impaired in vitro.

520  Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation
     Shenghong Yang, Yu Imamura, Russell W. Jenkins, Israel Cañadas, Shunsuke Kitajima, Amir Aref, Arthur Brannon, Eiji Oki, Adam Castoreno, Zehua Zhu, Tran Thai, Jacob Reibel, Zhirong Qian, Shuji Ogino, Kwok K. Wong, Hideo Baba, Alec C. Kimmelman, Marina Pasca Di Magliano, and David A. Barbie
     Autophagy inhibition has been proposed for treatment of KRAS-driven cancer, but this strategy resulted in a protumorigenic feedback loop that activated TBK1 and induced PD-L1 expression. Therapeutic approaches that counteract this feedback may be necessary to limit pancreatic dysplasia.

531  Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
     Bruce D. Freimark, Jian Gong, Dan Ye, Michael J. Gray, Van Nguyen, Shun Yin, Michaela M.S. Hatch, Christopher C.W. Hughes, Alan J. Schroit, Jeff T. Hutchins, Rolf A. Brekken, and Xianning Huang
     Blocking phosphatidylserine (PS) with antibodies reprograms the tumor microenvironment from immunosuppressive to immunosupportive and reactivates innate and adaptive antitumor immunity. Combining PS targeting with immune checkpoint blockade improved the therapeutic efficacy of both approaches in two preclinical tumor models.
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick, Shaun O’Brien, Jing Sun, Veena Kapoor, Steven Maceyko, Albert Lo, Ellen Puré, Edmund Moon, and Steven M. Albelda

Insertion of the small transgene RIAD augmented the efficacy of CAR T cells in solid tumors by blocking the inhibitory activity of PKA. This reduced immunosuppression by adenosine and PGE₂, while enhancing CAR T cells trafficking into tumors.

About the Cover
When tumors contain the oncogenic form of KRAS, their progression is aided by autophagy, a process by which cellular protein and organelles are degraded by the cell and become a source of energy. Thus, inhibiting autophagy is being considered as a treatment for these tumors. However, Yang and colleagues found that blocking autophagy in the pancreas permitted the accumulation of activated TBK1, a situation that increased protumorigenic inflammation. By blocking autophagy at the level of TBK1 with the inhibitor CYT387, chemokine production and granulocyte recruitment were also inhibited and KRAS-induced dysplasia was decreased. The cover art (left) is based on a figure in the original article (right, Fig. 2C). It shows the accumulation of phosphorylated TBK1 in autophagosomes when autophagy is inhibited. Artwork by Lewis Long.

Read more starting on page 520 of this issue of Cancer Immunology Research.
Cancer Immunology Research

4 (6)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://cancerimmunolres.aacrjournals.org/content/4/6">http://cancerimmunolres.aacrjournals.org/content/4/6</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://cancerimmunolres.aacrjournals.org/content/4/6">http://cancerimmunolres.aacrjournals.org/content/4/6</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>